Last reviewed · How we verify

CD40 agonist monoclonal antibody CP-870,893

Abramson Cancer Center at Penn Medicine · Phase 1 active Biologic Quality 0/100

CD40 agonist monoclonal antibody CP-870,893 is a Biologic drug developed by Abramson Cancer Center at Penn Medicine. It is currently in Phase 1 development. Also known as: CP-870,893.

At a glance

Generic nameCD40 agonist monoclonal antibody CP-870,893
Also known asCP-870,893
SponsorAbramson Cancer Center at Penn Medicine
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about CD40 agonist monoclonal antibody CP-870,893

What is CD40 agonist monoclonal antibody CP-870,893?

CD40 agonist monoclonal antibody CP-870,893 is a Biologic drug developed by Abramson Cancer Center at Penn Medicine.

Who makes CD40 agonist monoclonal antibody CP-870,893?

CD40 agonist monoclonal antibody CP-870,893 is developed by Abramson Cancer Center at Penn Medicine (see full Abramson Cancer Center at Penn Medicine pipeline at /company/abramson-cancer-center-at-penn-medicine).

Is CD40 agonist monoclonal antibody CP-870,893 also known as anything else?

CD40 agonist monoclonal antibody CP-870,893 is also known as CP-870,893.

What development phase is CD40 agonist monoclonal antibody CP-870,893 in?

CD40 agonist monoclonal antibody CP-870,893 is in Phase 1.

Related